I-BET-762是一种BET (bromodomain and extra terminal domain)蛋白抑制剂, IC50约为35 nM,抑制巨噬细胞产生促炎蛋白,抑制急性炎症,对其他溴区结合域包含的蛋白具有高度的选择性。
别名:GSK525762
I-BET-762是一种BET (bromodomain and extra terminal domain)蛋白抑制剂, IC50约为35 nM,抑制巨噬细胞产生促炎蛋白,抑制急性炎症,对其他溴区结合域包含的蛋白具有高度的选择性。I-BET-762抑制BET(溴区和额外的末端结构域) 蛋白, BRD2, BRD3 和 BRD4, 结合到BET的串联溴区,Kd为50.5-61.3 nM, 在FRET分析中,置换BET串联溴区的一种四乙酰化的H4肽,IC50为32.5-42.5 nM。I-BET-762占据BET蛋白的乙酰基-赖氨酸结合口袋,并抑制BET蛋白结合到乙酰化的组蛋白,从而破坏了炎性基因表达必不可少的染色质复合物的形成。分化过程中的第2天使用I-BET-762处理,改变CD4+T细胞的细胞因子产生,上调一些抗炎基因产物的表达,并下调一些促炎细胞因子的表达。
JCI Insight. 2022 Sep 8;7(17):e151851.
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition
体外实验* | |
---|---|
细胞系 | isolated CD4+ T cells |
方法 | CD4+ T cells are isolated from lymph nodes and spleens of 10- to 12-wk-old 2D2 transgenic mice by using Invitrogen Dynal Beads according to manufacturer’s protocols. The isolated CD4+ T cells were stimulated with platebound anti-CD3 and anti-CD28 antibodies alone (ThN conditions), or in the presence of anti-IL4 and IL-12 (Th1 conditions), IL-4 and anti-IL12 (Th2 conditions), IL-1β, IL-6, and IL-23 (Th17 conditions), or TGF-β (Treg conditions). Along with the cytokine mixtures were included either the Control-768 (GSK525768A) or I-BET-762 (GSK525762A) compounds. The cells are stimulated in these condition for 60–72 h and then harvested and expanded with DMEM media containing 10% (vol/vol) FBS, antibiotics, Lglutamine, and B-2ME. The cells were counted and reset to 0.5 × 106 cells per mL on days 3 and 4 after initial stimulation. Over the course of 5 d of T-cell culture and expansion, the compounds were diluted 12-fold relative to the starting concentrations. In case of Th1, Th2, and iTreg conditions, IL-2 was added to the media at a final concentration of 20 units per mL. On day 5 after initial activation, the cells were harvested and restimulated with PMA (10 nM) and ionomycin (1 μM) for 6 h. Brefeldin A (10 μg/mL) was added during the last 2 h of stimulation. Subsequently, the cells were fixed with 4% (wt/vol) paraformaldehyde in PBS for 15 min at 25 °C, washed in PBS, and permeabilized in saponin buffer [PBS, 0.5% saponin (Sigma), 1% (wt/vol) BSA, and 0.1% (wt/vol) sodium azide]. Intracellular staining was performed as described for indicated cytokines. In some experiments, cell surface staining was completed before fixation. |
浓度 | 125, 250, 500nM |
处理时间 | 60-72h |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
体内实验* | |
---|---|
动物模型 | LPS-induced endotoxic shock of C57BL/6 mice model |
配制 | 20% beta-cyclodextrin, 2% DMSO in 0.9% saline |
剂量 | 30 mg/kg |
给药处理 | retro-orbital or tail vein injection |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
分子量 | 423.9 |
分子式 | C22H22ClN5O2 |
CAS号 | 1260907-17-2 |
溶解性(25°C) | DMSO |
储存条件 |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.359 mL | 11.7952 mL | 23.5905 mL |
5 mM | 0.4718 mL | 2.359 mL | 4.7181 mL |
10 mM | 0.2359 mL | 1.1795 mL | 2.359 mL |
小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 | |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km 系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
[2] Delmore JE, et al. Cell. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
[3] Nicodeme E, et al. Nature. Suppression of inflammation by a synthetic histone mimic.
其他相关的Epigenetic Reader Domain产品 |
---|
Phoenixin-20
Phoenixin-20 (PNX-20) 是一种在脊椎动物体内具有激素样作用的生物活性肽,可以刺激下丘脑-垂体-性腺激素,调节哺乳动物的生殖过程。 |
Menin-MLL inhibitor 31
Menin-MLL inhibitor 31 是 menin-MLL 相互作用的有效抑制剂,IC50值为4.6 nM。 |
OPN-2853
OPN-2853是一种溴结构域蛋白-4 (BRD4) 抑制剂,可用于血液及淋巴系统疾病的相关研究。 |
HDAC/JAK/BRD4-IN-1
HDAC/JAK/BRD4-IN-1 是一种有效的 HDAC/JAK/BRD4 三重抑制剂。 |
VYN-201
VYN-201是一种新型泛BET抑制剂,可用于特发性肺纤维化的相关研究。 |
产品仅供科学研究或药证申报的用途使用,不为任何个人或者非科研性质的其他用途提供服务。
Copyright © 2010-2022 AbMole版权所有 沪ICP备16047849号 沪公网安备 31011502012228号